

# Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss

NCT05005039

---

Status	RECRUITING
Sponsor	University Hospital, Lille
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Postmenopausal women (defined as last menses  $>12$  months)
- Obesity with a BMI  $\geq 35$  kg/m<sup>2</sup>,
- Patients with an indication for bariatric surgery with two surgical techniques, RYGB and SG, but who have never had a bariatric surgery procedure previously,
- Enrollment will be stratified for each surgical techniques, RYGB and SG, by preoperative diabetes status, defined by having HbA1c  $>6.5\%$  or a prior physician's diagnosis of diabetes plus use of an antidiabetic medication.
- Patients who have signed the informed consent.

### Exclusion (3)

- women who were pre- and perimenopausal and men in order to minimize sex hormone and BMA changes unrelated to the surgical procedure.
- women who used medications known to impact bone metabolism or BMA, including bisphosphonates, teriparatide, denosumab, hormone replacement therapy (HRT) and oral glucocorticoids ( $>5$ mg prednisone equivalent daily for  $>10$  days in the last 3 months).
- any contraindication to magnetic resonance imagery (MRI).

## Locations (1 total)

---

Hopital Roger Salengro, CHU Lille, Lille, France